Therapeutic roles of peroxisome proliferator-activated receptor agonists.

By Bart Staels, J. Fruchart. Diabetes, 2005

661 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/1b5b96c8f4e59376fdb5601bdf2a5336f103636c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Christopher K. Glass
2. Bart Staels
3. Johan Auwerx
4. Mitchell A. Lazar
5. Michael G. Rosenfeld
6. B. Spiegelman
7. L. Michalik
8. W. Wahli

In Physiology

1. B. Spiegelman
2. Johan Auwerx
3. Mitchell A. Lazar
4. L. Michalik
5. W. Wahli
6. S. O’Rahilly
7. Christopher K. Glass
8. Takashi Kadowaki

Citations in the corpus

• International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors (2006, background): “Because of their various metabolic and therapeutic actions, PPARs have become major drug targets (Berger et al., 2005; Staels and Fruchart, 2005).”
• Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. (2007, background): “…agonists are associated with unwanted side effects: e.g., PPARg agonists promote weight gain and edema formation in diabetic patients (Staels and Fruchart, 2005; Yki-Jarvinen, 2005), whereas LXR agonists have been shown to cause marked hypertriglyceridemia in animals, at least in part due to…”